By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Canaccord Genuity has cut its price target on Gen-Probe's stock to $75 from $88, saying that there appears to be no competitive bids to acquire the molecular diagnostics firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.